Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ZymoGenetics, a developer of protein therapeutics, has promoted Douglas Williams, the company's president, to the position of CEO, effective January 2, 2009. At that time, Bruce Carter will retire from the position and will continue to serve as chairman of the board of directors in a nonexecutive capacity.
Subscribe to our email newsletter
Dr Williams has more than 20 years of experience in the biotechnology industry. At Immunex, he was head of discovery research, executive vice president and chief technology officer and a member of the board of directors.
After Immunex was acquired by Amgen in 2002, Dr Williams joined the strategic development team of Genesis R&D, a New Zealand-based biotechnology company, and later served as Seattle Genetics’s chief scientific officer.
Mr Carter said: “It has been an honor to lead ZymoGenetics and a privilege to work with so many bright and talented people. It is also satisfying to think that discoveries at ZymoGenetics have led to lives saved.
“In many ways it is sad to leave, but all organizations are invigorated by new blood, and I am confident that in Doug we have the right person to drive this company forward and capitalize on the opportunities we have created for patients and shareholders.”